News & Insights
Stay Informed With Our Latest Updates
Explore our comprehensive collection of news and in-depth insights spanning practice areas, industries, and regions.
Firm News November 12, 2025
Gibson Dunn Advising Damora Therapeutics on Sale to Galecto and on $285 Million Private Placement by Galecto
Gibson Dunn is advising privately held biotechnology company Damora Therapeutics, Inc. on its sale to Galecto, Inc.
Firm News October 28, 2025
Gibson Dunn Advised X4 Pharmaceuticals on Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Gibson Dunn advised X4 Pharmaceuticals on its public offering of common stock and full exercise of the underwriters’ option to purchase additional shares for gross proceeds of $155.3 million
Firm News October 10, 2025
Gibson Dunn Represented Apogee Therapeutics on $345 Million Offering of Common Stock and Pre-Funded Warrants
Gibson Dunn represented Apogee Therapeutics, Inc., a clinical-stage biotechnology company, in a public offering of 8,048,782 shares of common stock, including the full exercise of the underwriters' option to purchase an additional 1,097,561 shares.
Firm News October 8, 2025
Gibson Dunn Advises XOMA Royalty on Establishing At-The-Market Facilities for the Sale of Shares of Common Stock and Depositary Shares
Gibson Dunn advised XOMA Royalty Corporation on establishing an at-the-market facility for the sale of up to $75 million of shares of its common stock and an at-the-market facility for the sale of up to $50 million of its depositary shares.